FDA Approved: NUBEQA — Original Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved NUBEQA (darolutamide) through an original application for the treatment of non-metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-metastatic Castration-resistant Prostate Cancer

Drugs mentioned

• Nubeqa (darolutamide)

Snippet

ORIG AP for NUBEQA (DAROLUTAMIDE)